Dept. Cellular & Molecular Pharmacology, Rosalind Franklin, Univ.of Medicine & Science, USA.
Physiology Graduate Training Program, Univ. Wisconsin-Madison, School of Medicine &Public Health, USA.
Neuropharmacology. 2018 Sep 15;140:302-309. doi: 10.1016/j.neuropharm.2018.07.033. Epub 2018 Aug 4.
Opioid neurotransmission has been implicated in psychiatric disorders featuring impaired control over appetitive motivation, such as addiction and binge-eating disorder. We have previously shown that infusions of the μ-opioid receptor (μOR) agonist DAMGO into the ventromedial prefrontal cortex (vmPFC) induced hyperphagia, increased motor activity, and augmented sucrose-reinforced responding in the task progressive ratio (PR) task, which assesses the motivational value of an incentive. These effects were not reproduced by intra-PFC infusion of a variety of dopamine (DA) agonists and antagonists, suggesting that manipulation of intra-PFC DA systems alone is not sufficient to reproduce μOR-like effects. Nevertheless, this does not rule out interactions between PFC DA and μ-opioid systems. Here we used intra-vmPFC drug cocktails containing DAMGO and SCH 23390 (a DA D1 receptor antagonist) to determine whether increases in appetitive motivation and motor activity elicited by intra-vmPFC μOR stimulation require intact signaling through vmPFC D1 receptors. Blockade of D1 receptors with SCH 23390 attenuated the enhancement of PR breakpoint, and increases in exploratory-like behavior and feeding initiation elicited by intra-vmPFC μOR stimulation. These results establish that intra-vmPFC D1 signaling is required for the expression of behavioral effects evoked by μOR stimulation within the PFC, and further suggest that D1 tone plays an enabling or permissive role in the expression of μOR -elicited effects. Simultaneous targeting of both μ-opioid and D1 systems may represent a more efficacious treatment strategy (compared to μOR blockade alone) for psychiatric disorders characterized by dysregulated appetitive motivation.
阿片类神经递质传递与精神疾病有关,这些疾病的特征是对食欲动机的控制受损,例如成瘾和暴食障碍。我们之前的研究表明,将 μ 阿片受体 (μOR) 激动剂 DAMGO 输注到腹内侧前额叶皮层 (vmPFC) 会导致过度进食、增加运动活动,并在评估奖励动机价值的任务渐进比率 (PR) 任务中增强蔗糖强化反应。这些效应不能通过 PFC 内各种多巴胺 (DA) 激动剂和拮抗剂的输注来重现,这表明单独操纵 PFC 内的 DA 系统不足以重现 μOR 样效应。尽管如此,这并不能排除 PFC DA 和 μ 阿片系统之间的相互作用。在这里,我们使用含有 DAMGO 和 SCH 23390(一种 DA D1 受体拮抗剂)的 vmPFC 内药物鸡尾酒来确定 vmPFC μOR 刺激引起的食欲动机和运动活动增加是否需要 vmPFC D1 受体的完整信号传导。D1 受体拮抗剂 SCH 23390 阻断减弱了 vmPFC μOR 刺激引起的 PR 突破点、探索样行为和摄食启动的增加。这些结果表明,vmPFC D1 信号对于 PFC 内 μOR 刺激引起的行为效应的表达是必需的,并且进一步表明 D1 调谐在 μOR 诱导的效应的表达中起允许或许可作用。同时靶向 μ 阿片和 D1 系统可能代表一种更有效的治疗策略(与单独阻断 μOR 相比),用于治疗以食欲动机失调为特征的精神疾病。